Clinical Trials for Uterine Cancer

Pragmatic Pilot Study of ctDNA Informed Immune Checkpoint Inhibitor De-escalation in Advanced/Recurrent Mismatch Repair Deficient (MMR-D)/Microsatellite Instability High (MSI-H) Endometrial Cancer Using Standard of Care Treatments

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

TrialFetch AI summary: Adults with stage III (residual), stage IV, or recurrent MMR-D/MSI-H endometrial carcinoma eligible for standard first-line chemotherapy plus immune checkpoint inhibitor (no prior PD-1/PD-L1/CTLA-4 therapy; treated/stable brain metastases allowed). All receive usual chemo-immunotherapy and maintenance ICI, with a ctDNA blood test at ~1 year used to guide de-escalation: ctDNA-negative patients consider stopping maintenance ICI while ctDNA-positive patients continue maintenance ICI per standard care.

ClinicalTrials.gov ID: NCT07270666

An Open-label, Phase 1a/1b, Dose Escalation and Dose Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PHST001 in Adult Patients With Advanced Relapsed and/or Refractory Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolls adults with ECOG 0–1 and advanced relapsed/refractory solid tumors after standard therapy; dose escalation includes broad solid tumors including primary CNS tumors, while expansion focuses on ovarian cancer, endometrial cancer, and cholangiocarcinoma. Treatment is PHST001, a humanized IgG4 anti-CD24 antibody intended to block CD24–Siglec-10 innate immune checkpoint signaling and enhance macrophage phagocytosis, given as monotherapy or with chemotherapy backbones such as paclitaxel, topotecan, doxorubicin, FOLFIRI, FOLFOX, or gemcitabine.

ClinicalTrials.gov ID: NCT06840886

A Phase I First-in-human, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced solid tumors after progression on, or ineligibility for, standard therapies receive intravenous SIM0505 every 21 days. This CDH6-targeted antibody–drug conjugate delivers a topoisomerase-I inhibitor; dose optimization focuses on platinum-resistant ovarian, primary peritoneal or fallopian-tube cancer, clear-cell or papillary renal cell carcinoma, uterine serous carcinoma, and CDH6-expressing NSCLC adenocarcinoma without an actionable EGFR mutation.

ClinicalTrials.gov ID: NCT06792552

A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects With Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This study enrolls patients with incurable locally advanced or metastatic epithelial solid tumors, particularly NSCLC, who have measurable disease and ECOG performance status 0–1. Patients receive intravenous BL-B01D1 (izalontamab brengitecan), an investigational EGFR/HER3-targeting bispecific antibody–drug conjugate that delivers a topoisomerase I inhibitor, on one of two 21-day dosing schedules.

ClinicalTrials.gov ID: NCT05983432

A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Subjects With Selected Tumor Types

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, progressing ovarian or endometrial cancer are the main population; dose-escalation cohorts also include metastatic triple-negative breast cancer and non-small-cell lung adenocarcinoma. Patients receive intravenous farletuzumab ecteribulin (MORAb-202), an investigational FRα-targeting antibody–drug conjugate that delivers eribulin; one cohort also receives short-course corticosteroids to assess whether they reduce ILD.

ClinicalTrials.gov ID: NCT04300556

A Phase 1/2, Open-label, Dose-escalation, and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Therapeutic Activity of GI-101 As a Single Agent and in Combination with Pembrolizumab, Lenvatinib or Local Radiotherapy in Patients with Advanced or Metastatic Solid Tumors (Keynote B59)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic solid tumors, measurable disease, and ECOG performance status 0–1 receive GI-101 or GI-101A alone or in combination with pembrolizumab; GI-101 may also be combined with lenvatinib or local radiotherapy. GI-101 is a CD80–IL-2-variant fusion protein designed to counter CTLA-4-mediated suppression and stimulate cytotoxic T and natural-killer cells; GI-101A is a manufacturing-optimized formulation.

ClinicalTrials.gov ID: NCT04977453

A Phase 1a/1b Study to Evaluate the Safety and Tolerability of STK-012 As a Single Agent and in Combination Therapy in Patients with Selected Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients with selected advanced solid tumors receive STK-012 alone or with pembrolizumab, with some cohorts also receiving pemetrexed and carboplatin; most dose-escalation cohorts require prior standard therapy, while some expansion cohorts allow untreated metastatic disease, including PD-L1-negative NSCLC. STK-012 is an investigational IL-2 receptor α/β-biased partial agonist designed to preferentially stimulate antigen-experienced CD25-positive T cells.

ClinicalTrials.gov ID: NCT05098132

A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls patients with unresectable or metastatic KRAS G12C-mutant solid tumors, including NSCLC, colorectal cancer, and pancreatic cancer, generally after standard therapy; a cohort includes previously untreated advanced NSCLC. Patients receive olomorasib, an oral inhibitor that binds inactive KRAS G12C, alone or with pembrolizumab, cetuximab, or pembrolizumab plus pemetrexed and platinum chemotherapy, depending on cohort.

ClinicalTrials.gov ID: NCT04956640

A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with relapsed or metastatic solid tumors after standard therapy, including selected breast, ovarian, biliary tract, endometrial, and squamous non-small cell lung cancers, receive AZD8205 alone or in combination with rilvegostomig and/or saruparib. AZD8205 is a B7-H4–targeted antibody–drug conjugate that delivers a topoisomerase I inhibitor payload.

ClinicalTrials.gov ID: NCT05123482

A Phase 1 Study of SGN-B6A in Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This study enrolls patients with measurable metastatic or unresectable solid tumors and ECOG 0–1, including previously treated patients in monotherapy cohorts and treatment-naive patients with advanced NSCLC, head and neck, or esophageal cancer in combination cohorts. Patients receive sigvotatug vedotin, an integrin β6–targeting antibody–drug conjugate that delivers the microtubule-disrupting payload MMAE, alone or with pembrolizumab, with or without platinum chemotherapy.

ClinicalTrials.gov ID: NCT04389632